These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 18056048)

  • 1. Rationale for using nitric oxide donor therapy for prevention of bone loss and treatment of osteoporosis in humans.
    Wimalawansa SJ
    Ann N Y Acad Sci; 2007 Nov; 1117():283-97. PubMed ID: 18056048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nitric oxide and bone.
    Wimalawansa SJ
    Ann N Y Acad Sci; 2010 Mar; 1192():391-403. PubMed ID: 20392265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nitroglycerin therapy is as efficacious as standard estrogen replacement therapy (Premarin) in prevention of oophorectomy-induced bone loss: a human pilot clinical study.
    Wimalawansa SJ
    J Bone Miner Res; 2000 Nov; 15(11):2240-4. PubMed ID: 11092405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The influence of hormonal replacement therapy on bone density in postmenopausal women depending on polymorphism of vitamin D receptor (VDR) and estrogen receptor (ER) genes].
    Brodowska A
    Ann Acad Med Stetin; 2003; 49():111-30. PubMed ID: 15552843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hormone replacement therapy and its derivatives in the prevention and treatment of osteoporosis].
    Lamy O; Krieg MA
    Rev Med Suisse Romande; 2002 Aug; 122(8):377-81. PubMed ID: 12357730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Sex hormones and osteoporosis: a physiological perspective for prevention and therapy].
    da Silva JA; Porto A
    Acta Med Port; 1997 Oct; 10(10):689-95. PubMed ID: 9477594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective estrogen receptor modulators: A possible new treatment of osteoporosis in males.
    Kastelan D; Giljevic Z; Kraljevic I; Korsic M
    Med Hypotheses; 2006; 67(5):1052-3. PubMed ID: 16790322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular and molecular effects of growth hormone and estrogen on human bone cells.
    Kassem M
    APMIS Suppl; 1997; 71():1-30. PubMed ID: 9357492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis.
    Arthritis Rheum; 2001 Jul; 44(7):1496-503. PubMed ID: 11465699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nitric oxide as a mediator of estrogen effects in osteocytes.
    Joshua J; Kalyanaraman H; Marathe N; Pilz RB
    Vitam Horm; 2014; 96():247-63. PubMed ID: 25189390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reciprocal roles between caffeine and estrogen on bone via differently regulating cAMP/PKA pathway: the possible mechanism for caffeine-induced osteoporosis in women and estrogen's antagonistic effects.
    Zhou Y; Zhu ZL; Guan XX; Hou WW; Yu HY
    Med Hypotheses; 2009 Jul; 73(1):83-5. PubMed ID: 19278793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Estrogens and selective estrogen receptor modulators in the treatment of osteoporosis].
    Ribot C; Tremollieres F; Pouilles JM
    Ann Med Interne (Paris); 2000 Oct; 151(6):490-6. PubMed ID: 11104929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postmenopausal osteoporosis and hormone replacement therapy.
    Gambacciani M; Vacca F
    Minerva Med; 2004 Dec; 95(6):507-20. PubMed ID: 15785435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteoporosis: new hope for the future.
    Masi L; Bilezikian JP
    Int J Fertil Womens Med; 1997; 42(4):245-54. PubMed ID: 9309458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular cell signaling by membrane estrogen receptors.
    Hisamoto K; Bender JR
    Steroids; 2005; 70(5-7):382-7. PubMed ID: 15862821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogenesis and management of primary osteoporosis.
    Bauwens SF; Drinka PJ; Boh LE
    Clin Pharm; 1986 Aug; 5(8):639-59. PubMed ID: 3527528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A single intravenous administration of zoledronic acid prevents the bone loss and mechanical compromise induced by aromatase inhibition in rats.
    Gasser JA; Green JR; Shen V; Ingold P; Rebmann A; Bhatnagar AS; Evans DB
    Bone; 2006 Oct; 39(4):787-95. PubMed ID: 16844441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Postmenopausal hormonal treatment: conventional hormone replacement therapy or tibolone? Effects on bone].
    Reginster JY
    J Gynecol Obstet Biol Reprod (Paris); 2002 Oct; 31(6):541-9. PubMed ID: 12407324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study.
    Bagger YZ; Tankó LB; Alexandersen P; Hansen HB; Møllgaard A; Ravn P; Qvist P; Kanis JA; Christiansen C
    Bone; 2004 Apr; 34(4):728-35. PubMed ID: 15050905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hormone replacement therapy in postmenopausal women.
    Yasui T; Uemura H; Takikawa M; Irahara M
    J Med Invest; 2003 Aug; 50(3-4):136-45. PubMed ID: 13678382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.